US 8518981

I'll search for authoritative information on US 8518981, including any 2026 CAFC activity.

Let me look specifically for any 2026 appellate activity and a current litigation/status check.

US 8,518,981 B2 — Summary

Caveat on scope of search: I retrieved the authoritative patent document (Google Patents, FreePatentsOnline, Justia) and searched for Federal Circuit 2026 dockets referencing this number. I found no CAFC 2026 docket, appeal, or opinion involving US 8,518,981. The only 2026 palonosetron-related court activity surfaced is an Indian (Delhi High Court) decision on a different Helsinn patent (palonosetron + netupitant combination), which is not US 8,518,981. If a 2026 CAFC appeal exists for this patent, I could not verify it and cannot confirm it.

Bibliographic data (per authoritative patent text)

Sources: https://patents.google.com/patent/US8518981/en ; https://www.freepatentsonline.com/[8518981](/patent/8518981).html ; https://www.drugpatentwatch.com/p/patent/8518981

Spelling note (interpreted literally, not corrected): the Google Patents front matter gives the fourth inventor as "Andrew Miksztal." Related family documents render the name variously as "Andrew Mikształ" / "Andrew Mikszta." I am reporting the '981 record as written.

Family / priority

Application 13/087,012 is a continuation of US 11/186,311 (issued as US 7,947,724), which is a continuation of PCT/EP2004/000888 (published as WO2004/067005), claiming priority to US provisional 60/444,351 (filed Jan. 30, 2003). The '981 patent belongs to a large family (US 7,947,724; 7,947,725; 7,960,424; 8,598,218; 8,598,219; 8,729,094; 9,066,980; 9,125,905; 9,304,266; 9,457,020; 9,457,021; etc.).

Abstract (verbatim)

"The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments."

Independent claim — plain-language overview

The patent has 12 claims total, of which Claim 1 is the sole true independent claim. Claims 2–4, 6, 8–11 depend from Claim 1; Claims 5, 7, and 12 are product-by-process claims ("A single unit dose of palonosetron hydrochloride made by the method of claim 1/4/6").

Claim 1 — A method of manufacturing and terminally sterilizing a finished single-unit-dose vial of palonosetron (or a pharmaceutically acceptable salt), comprising:

• (a) providing one or more sterile open containers;
• (b) filling them with a pharmaceutically stable palonosetron solution;
• (c) sealing the filled containers;
• (d) terminally sterilizing the sealed, filled containers; and
• (e) optionally adjusting pH with HCl or NaOH before sealing.

The solution must:

• have a pH of about 4.0 to about 6.0;
• contain palonosetron hydrochloride at about 0.03 mg/mL to about 0.2 mg/mL (measured as free base);
• contain an aqueous carrier and a tonicity agent; and
• optionally contain one or a combination of mannitol, a chelating agent, and a citrate buffer.

In plain terms: this is a method claim covering the commercial process of filling vials with a low-concentration, pH-buffered palonosetron solution and then terminally sterilizing the sealed vials (i.e., sterilizing the final packaged product, rather than aseptic filling). The low dose (about 0.05 mg/mL, per Claim 2), the pH range, and the tonicity agent are the core limitations; mannitol/chelating agent/citrate buffer are optional in the base claim but become required in the dependents.

Product-by-process claims (5, 7, 12): cover a single unit dose of palonosetron hydrochloride produced by the method of Claim 4 (pH 4.5–5.5, HCl/NaOH pH adjuster, mannitol), Claim 6 (pH 4.5–5.5, HCl/NaOH, chelating agent + mannitol), or Claim 1 respectively.

Note on the specification vs. claim scope

The specification broadly describes stable solutions comprising 0.01–5 mg/mL palonosetron, pH 4.0–6.0, 10–100 mM citrate buffer, 0.005–1.0 mg/mL EDTA, and a chelating agent + mannitol carrier. However, the granted claims are narrower and method-focused, keyed to 0.03–0.2 mg/mL palonosetron HCl, a tonicity agent, and a terminal-sterilization step.

Litigation / validity context (with uncertainty flagged)

• The '981 patent was asserted in several Hatch-Waxman actions (e.g., D.N.J. 13‑5815, D. Del. 13‑1612, D. Del. 14‑1444, D. Del. 13‑688, D. Del. 15‑918), per https://www.drugpatentwatch.com/p/alphasignals/litigation/patent/8518981 and FDA correspondence.
• Important distinction: the well-known Federal Circuit on-sale bar decision Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), aff'd, 139 S. Ct. 628 (2019), concerned US 7,947,724, 7,947,725, 7,960,424, and 8,598,219 — not US 8,518,981. I therefore cannot state that the '981 patent was itself held invalid under the on-sale bar; the reported invalidity holding applied to its sibling patents.
• Google Patents records several 2013–2015 Delaware/New Jersey infringement suits and notes the family "has litigation." I did not find, and cannot confirm, any pending or decided 2026 appellate proceeding specifically for US 8,518,981.

Bottom line

US 8,518,981 is a Helsinn palonosetron formulation patent (filed April 14, 2011; issued Aug. 27, 2013; priority Jan. 30, 2003) claiming a method of manufacturing and terminally sterilizing single-unit-dose vials of a pH 4.0–6.0, ~0.03–0.2 mg/mL palonosetron HCl solution with a tonicity agent and optional mannitol/chelating-agent/citrate-buffer components. It has expired (anticipated 2024‑01‑30). No 2026 CAFC activity tied to this number was verifiable from my searches — treat any such claim as unconfirmed.

I'll research the litigation history for US patent 8518981. Let me search multiple sources.

Let me dig into specific case databases for the '981 patent.

I've reached the search-step limit, so here is the compiled analysis based on the sources retrieved. Note upfront: US 8,518,981 ("the '981 patent") is the formulation patent listed in the Orange Book for ALOXI® (palonosetron hydrochloride injection, NDA 021372). It issued August 27, 2013 — after the first wave of ALOXI ANDA litigation had begun — so it was typically added to existing cases by amended complaint/new complaint rather than initiating them. That is why '981 tends to appear as one of several patents-in-suit rather than as the sole asserted patent.

Confirmed litigation involving US 8,518,981

Additional ANDA filers who sent Paragraph IV letters on the '981 (and thus were potentially exposed to suit) include Mylan/Mylan Institutional (letter May 16, 2014), Gavis Pharma LLC (Dec. 31, 2014), and Par Pharmaceutical (2015); these names appear in the asserted-patent/notice-letter recitations of the co-pending ALOXI cases.

Outcomes and current status

• D.N.J. trial court (2015) — Helsinn win. Per Eisai's press release ("Successful Ruling in Patent Infringement Litigation for Antiemetic Agent ALOXI®," 2015), the U.S. District Court for the District of New Jersey ruled in favor of Helsinn, determining that certain formulation patent claims for ALOXI are valid and infringed by Teva's proposed generic. Coverage of ALOXI was reported as running through July 30, 2024 (patent term plus pediatric exclusivity), subject to appeal.
• Federal Circuit (2017) — reversed. Per Eisai's later release ("Patent Infringement Litigation for Antiemetic Agent ALOXI®," 2017), a Federal Circuit panel reversed the D.N.J. and ruled that certain patent claims covering ALOXI are not valid and are not infringed by Teva's generic palonosetron product. The release notes Teva still could not launch immediately pending further Federal Circuit/New Jersey court/FDA steps. Caveat: my searches did not return the appellate opinion text, so I cannot confirm with certainty whether the '981 claim(s) specifically, or only sibling formulation claims ('724/'725/'424), were the subject of the reversal. The 2017 appeal is generally reported as involving the ALOXI formulation patents; treat the precise claim-level mapping as unverified.
• Settlements. Helsinn settled with Sandoz (Jan. 2015) and Dr. Reddy's (Oct. 13, 2015), each permitting generic entry no earlier than Sept. 30, 2018 (earlier under certain circumstances). Other defendants (Exela, Fresenius Kabi, Hospira, etc.) were dismissed by settlement or voluntary dismissal.
• Effect of the '981 patent is now spent. The '981 patent expired January 30, 2024 (pediatric exclusivity to July 30, 2024). Google Patents shows the patent as "Expired – Fee Related," with anticipated expiration 2024‑01‑30. Ownership passed to Helsinn Advanced Synthesis SA / Helsinn Birex Pharmaceuticals Ltd / Helsinn Therapeutics (U.S.), Inc. (2018), with a security interest recorded to Hamilton SA LLC (2022) and released (2023).

PTAB proceedings (related, not the '981 itself)

Databases list post‑grant/IPR challenges to ALOXI-family patents — e.g., Accord's PGR on 8,598,219, Dr. Reddy's IPRs on 8,729,094 (IPR2015‑01550/‑01551/‑01553), and a PGR on 9,173,942 — but I did not find a PTAB trial instituted against 8,518,981 specifically. I cannot rule out that a petition naming the '981 exists; I simply have no retrieved evidence of one.

Important limitations on this answer

1. Sources are secondary (DrugPatentWatch, Google Patents' litigation links, PACER/RECAP dockets via CourtListener, Eisai/Helsinn press releases). I was unable to complete searches of the Unified Patents litigation portal and the Federal Circuit docket directly (search-step limit reached).
2. Individual case numbers in the D.N.J. 15-xxxx family and the D. Del. 13-2101/15-0918 cases are partially inferred from complaint recitations and Google Patents' page-level litigation links; verify against PACER before relying on them.
3. Do not treat the "outcome" column as final for the multi-defendant D.N.J. case — that litigation produced an evolving mix of settlements, a district-court judgment, and a Federal Circuit reversal, and the appellate claim-by-claim mapping onto the '981 is not fully verified here.
4. I have not auto-corrected any patent numbers; '981 = US 8,518,981 throughout, distinct from the related '724 (7,947,724), '725 (7,947,725), '424 (7,960,424), '218 (8,598,218), '219 (8,598,219) and '094 (8,729,094) patents.

If you need court-grade citations, the next step would be PACER dockets for D.N.J. 3:13‑cv‑05815, D. Del. 1:13‑cv‑01612, 1:14‑cv‑01444, and the Federal Circuit 2017 appeal, plus a direct Unified Patents litigation-portal query.

I'll verify the structured "no proceedings" default against public PTAB sources before finalizing.

Let me run final targeted confirmations on any '981-specific PTAB filing and the family's PTAB docket.

PTAB / AIA Trial Analysis — US 8,518,981 ("Liquid pharmaceutical formulations of palonosetron")

Bottom line up front: There are no AIA trial proceedings on file against US 8,518,981 — no IPR, no PGR, no CBM, and no derivation. The structured "PTAB proceedings on file" block (USPTO Open Data Portal) returns an empty set, and my independent web verification did not surface any petition, institution decision, or Final Written Decision naming the '981 patent. Do not let anyone tell you otherwise without a proceeding number. Below I explain the affirmative evidence, why the absence is real rather than a data gap, and what the surrounding family-level PTAB activity means for a defendant.

Proceedings overview

Total AIA trial proceedings naming US 8,518,981: 0. Breakdown: 0 active, 0 with claims invalidated, 0 with claims sustained, 0 settled, 0 institution-denied — because no proceeding was ever filed.

The bottom line for a defendant is therefore not "the patent is hardened" and not "the claims are canceled." It is: the '981 patent was never challenged at the PTAB at all, and it is now expired (anticipated expiration 2024-01-30; pediatric exclusivity ran to 2024-07-30). Practically, a demand letter invoking the '981 patent today is a demand built on an expired patent. There is no FWD to quote and no claim to have survived or died. The genuine defensive story for this patent lives in the district courts, not the Board — see the Strategic summary.

No proceedings on file — what I checked

• Canonical source (authoritative): the USPTO ODP-derived "PTAB proceedings on file" block supplied with this task states plainly: "The USPTO ODP API returns no AIA trial proceedings for this patent as of the most recent ingest." That is the controlling list.
• Independent web verification: searches for IPR/PGR/CBM petitions naming "8,518,981," and for palonosetron/Helsinn PTAB filings generally, returned only proceedings against sibling family members — US 8,598,219, US 8,729,094, and US 9,173,942. No petition, decision, or docket page was captioned to US 8,518,981.
• Corroborating primary document: Dr. Reddy's four concurrent '094 petitions affirmatively catalogued the '981's litigation history but did not include the '981 among the patents they challenged (they targeted only claims 22–27 and 30 of US 8,729,094). See IPR2015-01554, Petition (filed 2015-07-03), https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2015-01554/...

Why the absence is genuine, not a database blind spot:

1. IPR was available and nobody used it. The '981 issued 2013-08-27 and was asserted in Hatch-Waxman suits in late 2013 and 2014. Multiple well-funded ANDA filers (Dr. Reddy's, Sandoz, Teva, Accord, Aurobindo, Cipla, Mylan, Exela) each had a § 315(b) window. All of them filed—or declined to file—elsewhere in the family. The '981 was simply left alone.
2. PGR was almost certainly unavailable as a matter of law. PGR requires at least one claim with an effective filing date on or after 2013-03-16. Application 13/087,012 (filed 2011-04-14) is a straight continuation of US 11/186,311, which is a continuation of PCT/EP2004/000888 claiming priority to US provisional 60/444,351 (2003-01-30) — i.e., a purely pre-AIA chain. (This is my inference from the priority chain in the face of the patent, not a Board holding — flagging it as such.)
3. The '981 was dropped from the flagship litigation before trial. This is the key non-PTAB fact. Dr. Reddy's told the Board: "It is the undersigned's understanding that the assertions of infringement of the '981 and '218 Patents were dismissed." FDA's review record for NDA 203050 corroborates the timing: "Lawsuit filed on December 27, 2013 for patent 8518981, 8598218, 8598219. On May 29, 2014, lawsuit filed for patent 8518981 and 8598218 was dismissed." The June 2015 D.N.J. bench trial therefore turned on the '724, '725, '424, and '219 patents — the '981 was never tried, appealed, or IPR'd.

Cross-reference / refinement to the prior Litigation summary: that section correctly listed the '981 among the patents-in-suit in D.N.J. 3:13-cv-05815, but its "Status/Outcome" row could be read as implying the '981 rode through the 2015 D.N.J. judgment and the 2017 Federal Circuit reversal. It did not. The '981 assertions were dismissed in 2014, and the Helsinn v. Teva on-sale-bar appeal (855 F.3d 1356) addressed US 7,947,724, 7,947,725, 7,960,424, and 8,598,219 — the prior summary's own caveat is right, and I'd sharpen it to: no PTAB or appellate body ever adjudicated a claim of the '981 patent. This is a refinement, not a contradiction of the earlier section.

Adjacent PTAB proceedings — context ONLY (none is captioned to US 8,518,981)

These matter to a defendant as pattern signals about the patent owner, not as precedent on the '981. I am listing them strictly so the picture is complete, and I am labeling each patent number exactly as the sources state it.

PGR2014-00010 — Accord Healthcare, Inc. v. Helsinn Healthcare S.A.

• Type: Post-Grant Review
• Patent challenged: US 8,598,219 ('219) — not the '981
• Filed: 2014-09-02
• Status: Institution Denied; proceeding terminated 2014-11-24
• Judge panel: Jon Tornquist, Lora Green, Sheridan Snedden (per the PTAB docket aggregation)
• Petition grounds: claims 1–5 and 8 of the '219; the petition openly leveraged PGR's broader statutory scope to press a 35 U.S.C. § 112 attack (written description / enablement / claim scope), which is not available in IPR. Widely reported as the second-ever PGR filed.
• Institution decision: Denied 2014-11-24. Petitioner requested a fee refund on 2014-11-25 and the Board approved it 2014-12-15 — consistent with a denial of institution.
• FWD: None (never instituted).
• Settlement / termination: No — terminated by the institution denial, not by settlement.
• Appeal: None identified.
• Defensive value: None for the '981. Shows Helsinn's formulation family could blunt a § 112-flavored PGR attack at the institution stage.
• Data conflict flagged (interpreted literally, not auto-corrected): one aggregator (GreyB IPVerse) renders the respondent patent number for this proceeding as 8598219, while Docket Alarm and the MBHB/patentdocs PGR report both identify the patent as 8,598,219 ('219). I treat 8,598,219 as correct and note the discrepancy rather than silently harmonizing it.

Sources: https://sandbox.docketalarm.com/cases/PTAB/PGR2014-00010/Accord_Healthcare_Inc._v._Helsinn_Healthcare_S.A/ ; https://ipverse.greyb.com/ptab-web/cases/case-details/PGR2014-00010 ; https://patentdocs.org/2014/09/11/pgr-report-the-attack-of-35-usc-112/

IPR2015-01550 / IPR2015-01551 / IPR2015-01553 / IPR2015-01554 — Dr. Reddy's Laboratories, Ltd. & Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A. & Roche Palo Alto LLC

• Type: Inter Partes Review (four concurrent petitions, four distinct theories)
• Patent challenged: US 8,729,094 ('094) — not the '981
• Filed: 2015-07-03 (corrected petitions docketed 2015-07-21)
• Claims challenged: 22–27 and 30
• Status: Terminated by settlement after the parties' joint motion; DrugPatentWatch records a decision/termination date of 2015-10-14. None of the four had been instituted when terminated.
• Settlement / termination: Joint Motion to Terminate filed 2015-10-09 under 35 U.S.C. § 317(a) and 37 C.F.R. § 42.74, reciting that "this inter partes review proceeding has not been instituted" and that "the parties have settled their disputes." A joint request to treat the settlement agreement as business confidential was filed the same day. Terms are confidential. This tracks the DRL/Helsinn litigation settlement of 2015-10-13.
• FWD: None.
• Appeal: None.
• Defensive value: None for the '981. Demonstrates that Helsinn (and DRL) settled rather than fight these formulation patents to an FWD.

Sources: https://www.docketalarm.com/cases/PTAB/IPR2015-01550/Inter_Partes_Review_of_U.S._Pat._8729094/docs/10-09-2015-Patent_Owner/Motion-11-Joint_Motion_to_Terminate.pdf ; https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1462972](/patent/1462972)/ (business-confidential request, 2015-10-09)

PGR2016-00008 — Dr. Reddy's Laboratories, Ltd. & Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A.

• Type: Post-Grant Review
• Patent challenged: US 9,173,942 ('942) — not the '981
• Filed: 2016-02-05
• Claims challenged: 1–19
• Status: Institution Denied — 2016-08-17
• Judge panel: Toni R. Scheiner, Lora M. Green, Jacqueline Wright Bonilla, Administrative Patent Judges
• Institution decision: Denied under 35 U.S.C. § 324(a). The Board held that "Petitioner has failed to demonstrate that it is more likely than not that at least one claim of the '942 patent is unpatentable," and accordingly "we do not institute a post-grant review." Related proceedings noted in the decision: the '981 had been asserted in D.N.J. Nos. 11-3962, 11-5579, and 13-5815 (consolidated).
• FWD: None.
• Appeal: None identified.
• Defensive value: None for the '981; relevant only as evidence that the '942 (a still-later continuation-in-part) defeated a PGR at institution.

Source: PGR2016-00008, Decision Denying Institution (Paper 11, entered 2016-08-17), https://www.docketalarm.com/cases/PTAB/PGR2016-00008/Post_Grant_Review_of_U.S._Pat._9173942/

PGR2016-00007 — Dr. Reddy's Laboratories, Ltd. & Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A.

• Type: Post-Grant Review
• Patent challenged: US 9,173,942 ('942) — not the '981
• Filed: 2016-02-05 (filed concurrently with PGR2016-00008)
• Claims challenged: 1–6, 10, and 11, on obviousness grounds (per the Board's recitation in PGR2016-00008)
• Status: Not verified. PGR2016-00008's decision confirms this petition was filed; I could not retrieve PGR2016-00007's own institution decision or disposition before exhausting my search steps. I will not guess it. Verify at PTAB E2E if it matters.
• Defensive value: None for the '981.

Strategic summary

Which claims of 8,518,981 are canceled vs. sustained vs. untested? All twelve claims — Claim 1, dependent Claims 2–4 and 6 and 8–11, and product-by-process Claims 5, 7, and 12 — are untested. Not one claim has been construed, instituted, instituted-and-canceled, or sustained by the PTAB. The patent's claim scope is exactly as it issued on 2013-08-27, and it expired 2024-01-30 without ever being adjudicated in an AIA trial. Anyone who tells you a claim of the '981 was canceled is conflating it with the '219, '094, or '942.

Estoppel landscape. Because no AIA trial was ever instituted on the '981, there is no § 315(e)(2) estoppel, no § 325(e)(2) estoppel, and no estoppel-by-privity attaching to this patent from any petitioner. A defendant is not walled off from any ground. That said, the flip side is that there is also no PTAB record to borrow: no institution decision, no FWD reasoning, no Board claim construction, and no expert record from an AIA trial to repurpose in a district court. DRL's and Accord's § 112 and obviousness arguments in the sibling proceedings are not this patent's record, and their evidentiary exhibits (e.g., the Bonadeo and Repta declarations in PGR2014-00010) are useful only as a research roadmap, not as estoppel-laden admissions.

Pattern signals. Three observations for a defendant:

• Same petitioner, many targets, mixed results. Dr. Reddy's is the repeat player in this family (four concurrent '094 IPRs + two '942 PGRs), and it settled the IPRs rather than risk institution and lost institution on both '942 PGRs. Accord's one PGR was denied institution. The family has a strong record of surviving institution — but note this is a survival-at-institution story, not a merits story; no family FWD exists in my retrieved sources.
• The patent owner was not a PTAB appellant in this family. The genuinely consequential validity development — the Federal Circuit's on-sale-bar reversal in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) — came through district court litigation and a CAFC appeal, not the PTAB, and it concerned the '724/'725/'424/'219 patents. I found no PTAB-bench appeal by Helsinn on any palonosetron patent in my searches.
• No defensive aggregator. I found no Unified Patents or other aggregator petition on any member of this family. The challenges came from commercial ANDA rivals with direct litigation incentives.
• The '981 was strategically abandoned. Assertions of the '981 were dismissed in 2014 (per FDA's NDA 203050 record and DRL's IPR petition), before the June 2015 trial. The likely reason: the '981's method-of-manufacturing/terminal-sterilization claims (Claim 1) were harder to map onto a defendant's ANDA conduct than the composition/use claims of the '724/'725/'424/'219. That is a signal about assertability, not about validity — and it is the single most useful fact for a defendant reading this patent.

Recommended next steps

1. If you are a defendant and someone has asserted US 8,518,981 against you: lead with expiration, not with PTAB. The patent expired 2024-01-30 (anticipated; per Google Patents), with pediatric exclusivity to 2024-07-30. Any § 271(a)/(b) theory for ongoing conduct after that date fails on the patent's face. There is no FWD to quote because none exists — say that plainly and demand the asserting party identify its proceeding number.
2. Do not overlook the § 286 lookback. Expiration does not automatically extinguish a claim for past damages for pre-expiration acts within the six-year window of 35 U.S.C. § 286. If an assertor is pursuing historical sales or manufacturing, the defense shifts from "no liability" to claim construction and validity-in-district-court. Note the useful asymmetry: no IPR estoppel exists, so you can raise any § 102/§ 103 printed-publication ground in court, including art the sibling-patent petitioners used.
3. Reuse the family's art, but verify the record. The most-developed challenge record in this family is Accord's PGR2014-00010 petition (claims 1–5, 8 of the '219; § 112 grounds; Repta declaration Ex. 1015) and DRL's four '094 petitions (claims 22–27, 30; Bonadeo prosecution-history exhibits). Those challenge the sibling patents. If you need to attack the '981's Claim 1 (method of manufacturing and terminally sterilizing a single-unit-dose vial; pH 4.0–6.0; 0.03–0.2 mg/mL palonosetron HCl as free base; aqueous carrier; tonicity agent), that is a fresh analysis and a different claim type from anything the Board has seen.
4. If you are considering a filing: it is moot. IPR/PGR cannot be filed against an expired patent for prospective relief, and the nine-month PGR window for the '981 closed 2014-05-27 — assuming PGR was ever available to it, which (per my priority-chain inference above) it was not.
5. Verify at the primary source before you rely. Two items need to be confirmed directly: (a) whether any ex parte reexamination was ever requested on the '981 (outside the AIA-trial scope of this memo and not in my retrieved sources), and (b) the disposition of PGR2016-00007, which I could not verify. PTAB E2E (https://ptacts.uspto.gov) and the PTAB Decisions page are the primary sources.

Verification and limitations

• Structured data is authoritative here. The "no AIA trial proceedings" result from the USPTO ODP block is the controlling finding; my web search corroborated it rather than supplementing it.
• I did not fabricate any proceeding number. Every number above (PGR2014-00010, IPR2015-01550/-01551/-01553/-01554, PGR2016-00007, PGR2016-00008) comes from a retrieved source, and none of them is captioned to US 8,518,981. I have labeled each challenged patent explicitly.
• Unverified items, stated as such: the Board's precise reasoning for the PGR2014-00010 institution denial; the disposition of PGR2016-00007; and any ex parte reexamination history on the '981. Judge panels are reported for PGR2014-00010 and PGR2016-00008 only.
• Data conflict left intact, not corrected: GreyB IPVerse's "8598219" versus the "8,598,219" in Docket Alarm and the MBHB PGR report for PGR2014-00010.
• Date format throughout is YYYY-MM-DD per instruction.

I'll research the assignment record for US 8,518,981 across USPTO assignment databases and related sources.

I've reached my search-step limit. Below is the assignment analysis based on the authoritative Google Patents legal-events record for US 8,518,981, cross-referenced with the USPTO/family data surfaced in the patent text. WhereI could not retrieve a field (notably most reel/frame numbers and all correspondent data), I say so rather than guess.

Sourcing caveat up front: The USPTO Assignment Center (https://assignmentcenter.uspto.gov/) and the legacy Assignment Search (https://assignment.uspto.gov/patent/index.html) are the primary sources. I surfaced their contents only indirectly, through the Google Patents "Legal Events / Reassignment" block reproduced in the patent text provided to me. I retrieved a reel/frame for exactly one entry (047534/0024) and no correspondent/attorney-of-record data for any entry. Reel/frame and correspondent fields for the remaining links are therefore reported as "not retrieved," not as "none."

Inventors

Patterns worth flagging:

• Two clean employer blocs, matching the licensing split. The three Swiss/Italian inventors are Helsinn people; the three California inventors are Roche Palo Alto people. This maps exactly onto the 1998 Helsinn-from-Roche palonosetron license and the co-development arrangement described in the litigation record — not onto an inventor-departure or fire-sale pattern.
• The two inventor-assignment recordations mirror the blocs. The 2012‑09‑05 assignment runs from the Helsinn inventors to Helsinn Healthcare SA; the 2012‑11‑15 assignment runs from the Roche inventors to Roche Palo Alto LLC. The chain of title was perfected along employer lines.
• Unusual, non-inventor assignors on the Helsinn side. The 2012‑09‑05 Helsinn record lists assignors Enrico Braglia and Riccardo Braglia in addition to inventors Calderari, Bonadeo, and Cannella. The Braglias were the Helsinn managing directors/principals (successors to founder Gabriele Braglia) and are not named inventors on the '981. Their inclusion suggests they executed as rights-holders or officers rather than as inventors — worth verifying against the recorded document, but there is no evidence of a distressed or hurried transfer.
• No 12‑month inventor-departure pattern. I found no evidence of all (or any) named inventors leaving their assignees within 12 months of the 2011‑04‑14 filing. Calderari in particular remained a Helsinn officer decades later.

Spelling note (interpreted literally, not corrected): the '981 record prints inventor four as "Andrew Miksztal"; family documents variously render the name "Mikszta"/"Miksztal." Also, the 2012 Helsinn assignment record prints the assignor as "BONADEO, DANIEL" (not "Daniele"), and the 2018 record prints the assignee as "HELSINN BIREX PHARMACEUTIALS LTD." (sic). These are reported as written.

Original assignee

• On the face of the issued patent: Helsinn Healthcare SA (Lugano/Pazzallo, Switzerland) and Roche Palo Alto LLC (Palo Alto, CA, US) — a joint original assignee pair. Source: FreePatentsOnline/Google Patents front matter.
• Primary line of business.
  • Helsinn Healthcare SA — privately held Swiss specialty pharmaceutical group; business model is in-licensing/escalating drug candidates and out-licensing or co-promoting them. At the relevant time it had no U.S. sales force (per the D.N.J. trial record), which is why it partnered for U.S. distribution.
  • Roche Palo Alto LLC — U.S. subsidiary of the Roche group, holding the Syntex palonosetron estate (the '333 patent family). Roche had discontinued its own palonosetron development after Phase II in ~1997 and licensed the project to Helsinn in 1998, so Roche was not itself commercializing palonosetron.
• Did the original assignees ship a product embodying the claims? Yes, jointly attributable to the Helsinn side. The '981 is an Aloxi®-family formulation patent; ALOXI® (palonosetron HCl injection), NDA 021372, was approved July 25, 2003, and marketed in the U.S. by/through Helsinn (co-promotion with MGI Pharma, then Eisai/Helsinn Therapeutics). The '981 is the terminal-sterilization/low-concentration manufacturing patent in that estate.
• Current status.
  • Helsinn Healthcare SA — operating (private; Swiss). Ownership of the '981 was later spread to three Helsinn group entities (see timeline). In 2022 the group encumbered the estate with a security interest (Hamilton SA LLC), released in 2023.
  • Roche Palo Alto LLC — operating subsidiary, but it exited the '981 entirely by assigning its interest to Helsinn Healthcare SA effective/recorded 2016‑05‑11.

Assignment timeline

Every entry below is drawn from the Google Patents legal-events block for US 8,518,981. Reel/frame was retrievable for only the 2018‑11‑14 co-ownership entry (047534/0024). Correspondent-of-record was not retrievable for any entry. Google Patents presents a single date per event; I cannot tell from the retrieved data whether each date is the execution date or the recording date, so I present it as the date Google Patents lists and flag the ambiguity rather than assert one.

• 2011‑04‑14 (as listed) — Reel not retrieved

  • Conveyance: Application filed by / original assignment of interest (Google Patents labels this merely "Application filed by Helsinn Healthcare SA, Roche Palo Alto LLC")
  • Assignor: inventors (six, per Inventors table)
  • Assignee: Helsinn Healthcare SA and Roche Palo Alto LLC (joint)
  • Correspondent: not retrieved. No recurrence to flag.
  • Context: initial filing / establishment of joint ownership — a co-development arrangement, not a transfer.

• 2012‑09‑05 (as listed) — Reel not retrieved

  • Conveyance: Assignment
  • Assignor: BONADEO, DANIEL; BRAGLIA, ENRICO; BRAGLIA, RICCARDO; CALDERARI, GIORGIO; CANNELLA, ROBERTA
  • Assignee: HELSINN HEALTHCARE SA
  • Correspondent: not retrieved. No recurrence to flag.
  • Context: internal title-perfection — the Helsinn-side inventors (plus two non-inventor Helsinn principals) assigning their rights to the employer.

• 2012‑11‑15 (as listed) — Reel not retrieved

  • Conveyance: Assignment ("ASSIGNMENT OF ASSIGNORS INTEREST")
  • Assignor: LEE, KATHLEEN M.; MIKSZTAL, ANDREW; MALEFYT, THOMAS
  • Assignee: ROCHE PALO ALTO LLC
  • Correspondent: not retrieved. No recurrence to flag.
  • Context: internal title-perfection — the Roche-side inventors assigning their rights to the employer.

• 2016‑05‑11 (as listed) — Reel not retrieved

  • Conveyance: Assignment ("ASSIGNMENT OF ASSIGNORS INTEREST")
  • Assignor: ROCHE PALO ALTO LLC
  • Assignee: HELSINN HEALTHCARE SA
  • Correspondent: not retrieved. No recurrence to flag.
  • Context: consolidation of ownership — Roche's undivided interest transferred to Helsinn, leaving Helsinn Healthcare SA as sole owner of the '981.

• 2018‑11‑14 (as listed) — Reel 047534 / 0024

  • Conveyance: Patent Co-Ownership Agreement (a transfer creating co-ownership)
  • Assignor: HELSINN HEALTHCARE SA
  • Assignee: HELSINN ADVANCED SYNTHESIS SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTIALS LTD. (spelling as recorded)
  • Correspondent: not retrieved. No recurrence to flag.
  • Context: internal group reorganization — spreading title across three Helsinn affiliates so that the API manufacturer (Advanced Synthesis), the U.S. commercial entity (Therapeutics U.S.), and the Irish finished-product manufacturer (Birex) all co-own the estate.

• 2018‑11‑21 (as listed) — Reel not retrieved (document expressly corrects the prior record at reel 047534 frame 0024)

  • Conveyance: Corrective Assignment — to correct (1) the spelling of assignee name "Helsinn Birex Pharmaceuticals Ltd." and (2) the assignee addresses previously recorded at reel 047534 frame 0024
  • Assignor: HELSINN HEALTHCARE SA (confirming the patent co-ownership agreement)
  • Assignee: HELSINN BIREX PHARMACEUTICALS, LTD.; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN ADVANCED SYNTHESIS SA
  • Correspondent: not retrieved. No recurrence to flag — but note this is the same transaction as the prior entry, so if a correspondent appears on both, the recurrence would be trivially explained by the correction itself.
  • Context: correction only — no change in economic ownership.

• 2022‑12‑30 (as listed) — Reel not retrieved

  • Conveyance: Security Interest (grant of security)
  • Assignor (grantors): HELSINN BIREX PHARMACEUTICALS LIMITED; HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.
  • Assignee (secured party): HAMILTON SA LLC
  • Correspondent: not retrieved. No recurrence to flag.
  • Context: securitization / financing — a collateral pledge, not a sale or transfer of ownership. Hamilton SA LLC is the collateral agent/lender of record.

• 2023‑09‑20 (as listed) — Reel not retrieved

  • Conveyance: Release by Secured Party
  • Assignor (releasing party): HAMILTON SA LLC
  • Assignee (beneficiaries): HELSINN HEALTHCARE SA; HELSINN BIREX PHARMACEUTICALS LIMITED; HELSINN THERAPEUTICS (U.S.), INC.
  • Correspondent: not retrieved. No recurrence to flag.
  • Context: release / discharge — the 2022 security interest was extinguished; ownership reverts to its unencumbered form.

• (Not an assignment, but the chain's terminus) — 2024‑01‑30 anticipated expiration (Google Patents "Expired – Fee Related"); pediatric exclusivity to 2024‑07‑30.

Does the Assignment Center have records? Yes — the chain is fully recorded (eight post-filing event entries above). This is the opposite of the "no records / original assignee still owns it" default.

Timeline diagram

timeline
    title Ownership of US 8518981
    2011 : Application filed by Helsinn and Roche
    2012 : Helsinn inventors assign to Helsinn
         : Roche inventors assign to Roche Palo Alto
    2013 : Patent issued
    2016 : Roche interest assigned to Helsinn
    2018 : Co-ownership agreement among Helsinn entities
         : Corrective assignment recorded
    2022 : Security interest granted to Hamilton SA
    2023 : Security interest released
    2024 : Patent expired

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No assignee in the chain is a licensing-only LLC. The 2018 receivers are three operating Helsinn affiliates with identifiable functions (Helsinn Advanced Synthesis SA = API synthesis; Helsinn Birex Pharmaceuticals Ltd. = Irish finished-product plant, named in the D.N.J. record as the manufacturer; Helsinn Therapeutics (U.S.) Inc. = U.S. commercial entity, the named co-promoter of Aloxi in the June 2010 Eisai press release). Reel 047534/0024 effects an intra-group co-ownership spread, not a transfer to a shell. Hamilton SA LLC (2022) is a secured party, not an owner.

2. Known asserter in the chain — not present. No assignee matches the enumerated NPE lists (Acacia, Marathon, IV, IPNav, Wi‑LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation, Spangenberg entities, etc.). Caveat / nuance: Helsinn itself is a high-frequency patent plaintiff — the '981 estate was asserted in multiple Hatch‑Waxman suits (D.N.J. 3:13‑cv‑05815; D. Del. 1:13‑cv‑01612, 1:14‑cv‑01444, 1:15‑cv‑00918). But those are operating-company-vs-ANDA-filer suits under 35 U.S.C. § 271(e)(2), i.e., classic branded-pharma assertion against actual generic competitors — not NPE conduct.

3. Repeat correspondent across the chain — unclear (data not retrieved). I could not obtain the correspondent-of-record field for any of the eight entries, so I cannot call recurrence present or absent. Do not read this as "no repeat correspondent"; it is an evidence gap. The only attribution lead I recovered anywhere in the family file is that Arnall Golden Gregory LLP (Atlanta; phone 404‑873‑8500) was prosecuting counsel of record on related application 13/901,830 in 2013 — a prosecution address, which is a different role from the assignment-recording correspondent. Even if Arnall Golden Gregory appeared as correspondent on some recordings, a single firm doing family prosecution is not an NPE signal.

4. Cascading transfers — not present. The only two assignments in rapid succession (2018‑11‑14 and 2018‑11‑21) are a single transaction plus its corrective re-recording, not a chain of LLCs. There is no sequence of consecutive transfers through differently named entities within 24 months. The three 2018 co-owners share the Helsinn corporate name and are described in the record as affiliates, not anonymous vehicles.

5. Pre-litigation transfer — not present (as an NPE signal). The 2012‑09‑05 and 2012‑11‑15 assignments were recorded in the 2012 run-up to the 2013 suits, but they are inventor-to-employer title perfections, and the "assignees" (Helsinn, Roche) are the same entities named as original assignees on the 2011 filing. There was no transfer to a new, unrelated assertion vehicle within six months of the first suit. The 2016 Roche‑to‑Helsinn consolidation post-dates the 2013 suits and is a cleanup of co-ownership.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 proceeding or judicial sale appears anywhere in the chain. The 2022 Hamilton SA LLC entry is a consensual security interest, and it was released in 2023 — the inverse of a distressed liquidation.

7. Privateering — not present. Helsinn is both the patent owner and the product manufacturer/marketer (via Birex and Helsinn Therapeutics U.S.). It asserts in its own name and its affiliates' names against generic competitors; there is no arm's-length NPE asserting "on Helsinn's behalf."

8. Defensive aggregator — not present. The chain terminates (post‑release, 2023‑09‑20) back at the three Helsinn operating entities. It does not end at RPX, AST, LOT, Unified Patents, or OIN. No neutralizing acquisition occurred.

Verdict

Operating-company assertion.

The chain runs from a joint operating-company filing (2011‑04‑14, Helsinn Healthcare SA + Roche Palo Alto LLC), through inventor-to-employer title perfections (2012‑09‑05 and 2012‑11‑15), to a consolidation of 100% ownership in Helsinn Healthcare SA (2016‑05‑11), then an intra-group co-ownership spread among three genuinely operating Helsinn affiliates (2018‑11‑14, reel 047534/0024, corrected 2018‑11‑21), a consensual financing pledge to Hamilton SA LLC (2022‑12‑30), and a release of that pledge (2023‑09‑20). Every owner is an operating pharmaceutical manufacturer or its affiliate; the patent was asserted by those same entities against actual ANDA competitors under § 271(e)(2); and the estate expired 2024‑01‑30 without ever passing to a licensing-only vehicle. Zero of the eight NPE signals is present, one (repeat correspondent) is an unresolved evidence gap rather than a finding, and the verdict is therefore the non-NPE category.

Verify at the primary source: USPTO Assignment Center — search by patent number 8518981 — https://assignmentcenter.uspto.gov/ (legacy mirror: https://assignment.uspto.gov/patent/index.html), specifically to (a) pull the reel/frame for the 2011, 2012, 2016, 2018‑11‑21, 2022, and 2023 entries; (b) capture the correspondent-of-record on each; and (c) confirm the exact reel/frame cited in the 2018‑11‑21 corrective document (I have it as reel 047534 frame 0024).

I'll verify the key prior-art references against authoritative sources before compiling the § 102 analysis.

Prior-Art Analysis — US 8,518,981 B2 ("Liquid pharmaceutical formulations of palonosetron")

Source of record used: the front matter of US 8,518,981 B2 as published (Google Patents, https://patents.google.com/patent/US8518981/en; FreePatentsOnline, https://www.freepatentsonline.com/[8518981](/patent/8518981).html). The patent's own citation lists are reproduced below without correction of any number or name.

Threshold matters that govern every § 102 entry

1. Governing statute is pre‑AIA § 102. The '981 patent's provisional priority is January 30, 2003 (US 60/444,351 → PCT/EP2004/000888 → US 11/186,311 → US 13/087,012). Because the application never contained a claim with an effective filing date on/after March 16, 2013, pre‑AIA §§ 102(a)/(b)/(e) (and § 103) control. A reference is § 102 prior art only if it was (a) publicly known/patented/published before the invention date, (b) published/patented more than one year before Jan. 30, 2003 (i.e., before Jan. 30, 2002), or (e) a U.S. patent/publication filed before Jan. 30, 2003.

2. Anticipation requires all elements in one reference. '981 Claim 1 requires, together: (i) palonosetron hydrochloride 0.03–0.2 mg/mL (free‑base basis); (ii) solution pH 4.0–6.0; (iii) an aqueous carrier; (iv) a tonicity agent; (v) sealing and terminal sterilization of the filled single‑unit‑dose vial (optionally with HCl/NaOH pH adjustment). Claims 5, 7, 12 are product‑by‑process claims to a unit dose made by Claim 1/4/6; Claims 2–4, 6, 8–11 are narrow dependents (0.05 mg/mL; HCl/NaOH; mannitol; EDTA+mannitol; pH 4.5–5.5).

3. Consequence: A reference can only anticipate if it discloses palonosetron. Of the 35 front‑page patent citations, only one — US 5,202,333 — discloses palonosetron, and even it does not disclose the claimed pH/terminal‑sterilization/low‑concentration combination. No cited reference cleanly anticipates Claims 1–12 as issued; the bulk of the art functions as § 103 obviousness art. I flag this explicitly rather than manufacturing § 102 mappings that the record does not support.

A. The one citation that names palonosetron (the closest prior art)

*Note: the application number/issuance metadata for the '333 patent appear in varying forms across databases (Unified Patents lists app. 07/704,565, filed 1991‑05‑21 as a division, priority 1989‑11‑27). The controlling date for § 102 purposes is the 1989–1993 window, which places it well before the '981 priority date regardless.

Related same‑compound reference (from the family‑citation list): US 5,567,818 A (Syntex, Processes for preparing 2‑(1‑azabicyclo[2.2.2]oct‑3‑yl)‑1H‑benz[de]isoquinolin‑1‑one derivatives…, filed 1994‑07‑08, issued 1996‑10‑22) discloses/prepares palonosetron but teaches nothing about a terminally sterilized pH‑buffered vial formulation → § 103 art only; no § 102 anticipation of Claims 1–12.

B. Complete front‑page patent citation list (35 references) with § 102 treatment

B‑1. Same‑family / same‑applicant references — not prior art under § 102

B‑2. Other 5‑HT₃ "setron" reference patents (no palonosetron) — § 103 art only

B‑3. Reference patents/applications about other 5‑HT₃ drugs (granisetron) — § 103 art only

B‑4. General formulation / excipient / dosage‑form art (no palonosetron) — § 103 art only

B‑5. Same‑applicant method patents (treatment, not formulation) — § 102(e) candidates, but no anticipation

C. Family‑cited references (Google Patents "Family Cites Families (12)")

These were cited in the international family, not necessarily on the '981 U.S. face, but are part of the same art set:

D. Bottom line

• No cited reference anticipates Claims 1–12 of US 8,518,981 under § 102. Anticipation fails because (i) only US 5,202,333 even discloses palonosetron, and (ii) its Example 13 IV formulation is at pH 3.7 with 10–100 mg/mL drug and no terminal‑sterilization step — all three outside the claimed limitations (pH 4.0–6.0; 0.03–0.2 mg/mL; sealing + terminal sterilization of a single‑unit vial).
• The genuine prior‑art relationship for the '981 patent is § 103 obviousness, not § 102. The art splits into: (1) the palonosetron compound/formulation base (US 5,202,333; US 5,567,818; and, as § 102(e) candidates, Helsinn's WO 2004/045615); and (2) analogous "setron" injectable‑formulation art that supplies the pH‑buffer/tonicity‑agent (mannitol)/chelator (EDTA) elements (e.g., Roche's granisetron multidose‑vial patents US 6,294,548 / US 2001/0020029; Glaxo's ondansetron liquid/freeze‑dried patents). This is precisely the framing that the later IPR petitioner used against the sibling '724/'725/'424 patents (Petition, PTAB IPR2015‑01550 family, https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1458461](/patent/1458461)/…), and the framing the Federal Circuit addressed in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) (https://www.acc.com/sites/default/files/2019-08/Know%20Your%20IP%20-%20Supplemental%20Materials%20-%20August%[202019](/patent/202019).pdf) — which concerned the '724/'725/'424/'219 patents, not US 8,518,981.
• Not auto‑corrected: US 8,518,981 is treated as a distinct patent from its siblings US 7,947,724, US 7,947,725, US 7,960,424, US 8,598,218, and US 8,598,219 throughout, even though they share the same specification. The '981 front page renders inventor four as "Andrew Miksztal"; sibling documents render "Andrew Mikszta" / "Andrew Mikształ" — reported as written, not harmonized.

Uncertainty flags: (1) I could not retrieve the full text of the '333 patent claims or the WO 2004/045615 US counterpart's filing date to fix its exact § 102(e) date; treat that date as an estimate pending USPTO PatentCenter verification. (2) "Publication date" columns reproduce the priority/publication dates shown in the '981 front matter, whose "priority date" field for PCT filings is an assumption, as Google Patents itself notes.

Suggested next verification step: pull the USPTO PatentCenter file wrapper for app. 13/087,012 (and the parent 11/186,311) to confirm the exact examiner‑cited references, their § 102/§ 103 designations, and the declared priority date for any WO 2004/045615 U.S. counterpart.

Obviousness Analysis — US 8,518,981 B2 under 35 U.S.C. § 103

Building on the prior sections: this analysis assumes the claim construction, bibliographic data, and litigation posture already established for the '981 patent (12 claims; Claim 1 the sole independent claim; priority Jan. 30, 2003; issued Aug. 27, 2013; expired 2024‑01‑30). I do not repeat that material. One housekeeping note: the header of this task states the current date is April 26, 2026, while the environment used 2026‑09‑27 in earlier steps — I flag the inconsistency but it does not affect the § 103 analysis.

Governing law. The '981 application (Ser. No. 13/087,012) is a pre‑AIA continuation of a chain reaching back to US provisional 60/444,351 (Jan. 30, 2003). Pre‑AIA § 103 therefore governs, but the controlling obviousness standard is KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), applied through the Graham v. John Deere framework (scope/content of prior art; differences; PHOSITA level; secondary considerations). KSR is decisive here because every claimed element is a familiar, well‑known pharmaceutical‑formulation element combined in a predictable way ("the combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results").

1. The prior‑art set (as listed on the patent page)

I have grouped the cited references by the claim element each is positioned to supply. I have not auto‑corrected any number.

References on the page that are NOT available as prior art against the '981 claims (important not to mis-deploy them):

• US 7,947,724 B2; US 7,947,725 B2; US 7,960,424 B2; US 8,598,219 B2; WO2004/067005 A1 — same family/same Jan. 30, 2003 priority (the '981's own parents/siblings).
• WO2004/073714 A1 and US 2006/0074101 A1 — Helsinn, priority Feb. 18, 2003, i.e., after the '981 priority date.
• CN100336508C (2005), CN100455286C (2006), WO2010/077669 A2 (Teva, 2008) — all post‑date the priority date; they are evidence of the later state of the art only.
• The Aloxi approval letter (2003) and Aloxi PI (2008) are only prior art if the '981 claims are not entitled to the Jan. 30, 2003 priority date (see § 8).

2. Claim 1, element by element

Result of the mapping: the only differences between Claim 1 and US 5,202,333 Ex. 13 are (i) the shifted pH window (4–6 vs. 3.7), (ii) the ~100× lower palonosetron concentration, (iii) substitution of mannitol for dextrose as the tonicity agent, (iv) addition of EDTA, and (v) performance of terminal sterilization. Each of those differences is supplied by a secondary reference, and none of the references teaches away.

3. Combination A (primary obviousness theory)

US 5,202,333 (palonosetron) + Connors/Wells/Lachman + Handbook of Pharmaceutical Excipients + Won 1995 + DE19833119A1 + Parenteral Medications/Broadhead

Motivation, in the order a POSITA would reason:

1. Same field, same problem, express direction. US 5,202,333 is the primary reference — it discloses palonosetron and an aqueous injectable formulation. The '981 specification itself frames the problem against this reference, stating the '333 formulation "has a pH of 3.7 and a shelf stability of less than the 1‑2 year time period required by health authorities in various countries." An applicant's admission that the closest prior art fails a regulatory requirement is an express motivation to improve stability by exactly the levers claimed (pH, buffer, chelator, tonicity agent, terminal sterilization). KSR ("a need or problem … known in the field can provide the motivation").
2. pH was a known, result‑effective variable. Connors and Wells teach that degradation rate is a function of pH and that the optimum is located by routine pH‑rate screening. The patent's own Example 1 (screening pH 2.0, 5.0, 7.4, 10.0 and finding 5.0 best) is precisely the kind of "routine experimentation" that In re Applied Materials holds insufficient to confer patentability. KSR: "when there is a design need … to solve a problem and there are a finite number of identified, predictable solutions," the solution is obvious.
3. The specific excipients were known, interchangeable formulation tools. The Handbook of Pharmaceutical Excipients entries cited (pp. 140‑143, 191‑194, 324‑328; 6th ed. pp. 247‑250) teach citrate buffers, EDTA, and polyols such as mannitol as standard parenteral excipients. Swarbrick's Encyclopedia of Pharmaceutical Technology chapter is expressly devoted to the role of excipients in parenteral dosage forms.
4. Chelator rationale supplied by Won 1995 and DE19833119. Won et al. document photolytic and oxidative degradation of a 5‑HT₃ antiemetic agent (RGI2915) and the utility of stabilizing measures; DE19833119A1 describes a "storage‑stable injectable solution … [that] contains buffer, organic solvent, antioxidant and complexing agent." A POSITA seeking shelf life for a 5‑HT₃ antagonist would therefore add a chelator (EDTA) and a buffer to a pH‑optimized aqueous solution as a matter of routine design.
5. Terminal sterilization was standard and preferred. Lachman, Parenteral Medications, and Broadhead each teach terminal sterilization (e.g., autoclaving sealed containers) as a standard, validated alternative to aseptic filling. Terminal sterilization is the economically and (from a sterility-assurance standpoint) generally preferred route; the only design constraint it imposes is heat stability — which the pH/buffer/chelator combination is designed to deliver. The '981 specification confirms the inventors viewed terminal sterilization as the goal ("manufactured using non‑aseptic, terminal sterilization processes").
6. Tonicity agent. Since the claimed solution must be isotonic, and both the '333 reference (dextrose) and the Handbook (mannitol, dextrose, NaCl) teach the class, selecting mannitol is the kind of "substitution of one known element for another to obtain predictable results" that KSR deems obvious. The patent's own Example 3 (mannitol "showed superior stability" over sodium chloride) is evidence of a result, not of invention, absent proof that it was unpredictable — and the specification at the same time concedes mannitol was a known tonicifying agent at 41.5 mg/mL.

Bottom line for Combination A: Claim 1 would very likely have been prima facie obvious as a combination of the '333 reference with standard formulation references, absent rebuttal evidence.

4. Combination B (alternative primary reference — vial/unit‑dose framing)

US 6,294,548 B1 and/or US 2001/0020029 A1 (multidose vial formulations of a 5‑HT₃ antagonist) + US 5,202,333 (palonosetron) + Parenteral Medications/Lachman

This theory attacks the "finished single unit dose vial" and "terminally sterilizing" limitations. The granisetron multidose‑vial references show that putting a 5‑HT₃ antagonist into a sealed glass vial as a buffered, isotonic, preserved aqueous solution was conventional. A POSITA seeking a ready‑to‑use palonosetron vial would look to the vial formulations already commercialized for the same drug class (ondansetron, granisetron) and adapt them to palonosetron — a classic KSR "improvement" rationale. Combining that with the '333 palonosetron disclosure yields every element of Claim 1.

Additionally, Mayron (1996) confirms the stability of a setron in IV solutions and oral liquids, and the ondansetron/granisetron oral‑liquid references (US 5,854,270; US 5,955,488) supply the oral‑liquid variant described in the '981 specification (Example 5).

5. Combination C (the concentration limitation)

The 0.03–0.2 mg/mL limitation is the element most likely to draw a prima facie "weak" assessment, because US 5,202,333 Ex. 13 recites "Palonosetron HCl 10‑100 mg … to 1.0 mL" — i.e., orders of magnitude higher. Three lines of art close the gap:

1. Clinical/dose‑ranging art. Macciocchi et al. (ASCO 2002, abstract 1480) and Stacher (2002) report low IV palonosetron doses (the drug is "an order of magnitude more potent"); the Aloxi PI (2008) discloses 0.25 mg/5 mL = 0.05 mg/mL — squarely inside the claimed range.
2. WO2004045615A1 (Helsinn, prio. Nov. 15, 2002) — antedates the '981 priority date and is a candidate § 102(e) reference directed to palonosetron dosing for CINV.
3. Optimization rationale. The '981 specification states that "palonosetron concentration was also a critical factor in chemical stability, with greatest stability seen at the lowest palonosetron concentrations." Even if that directional result is counterintuitive, the range 0.03–0.2 mg/mL is broad and overlaps the clinically reported unit‑dose concentrations; concentration is a result‑effective variable (In re Applied Materials), and a POSITA reducing dose for a more potent drug (as the '981 specification itself says — "only 1/10th the amount") would land in the claimed range.

6. Dependent claims

None of claims 2–12 introduces an independent inventive concept:

• Claim 2 (0.05 mg/mL) — Aloxi PI / clinical dose art; the commercial unit dose.
• Claim 3 (HCl or NaOH pH adjuster) — expressly disclosed in US 5,202,333 Ex. 13 ("Sodium Hydroxide 0.18 mg").
• Claims 4, 6, 8–11 — mere permutations of the optional elements (mannitol, chelator, citrate buffer), each individually taught by the Handbook and the parenteral‑formulation treatises; a claim reciting one or a sub‑combination of known excipients adds nothing patentable.
• Claims 5, 7, 12 (product‑by‑process) — these are especially vulnerable. Under In re Thorpe, process limitations do not impart patentability to a product claim unless they produce a structurally different product. A "single unit dose of palonosetron hydrochloride" that is a solution of the known compound in a buffered, isotonic, EDTA‑containing aqueous vehicle is not structurally distinguishable from the prior‑art product; the terminal‑sterilization step does not change the product's structure. These claims should be analyzed as product claims for obviousness purposes and would stand or fall with the composition.

7. Rebuttal / secondary considerations Helsinn would (and did) advance

A complete § 103 analysis must weigh the Graham objective indicia. The record on the patent page shows disputes over exactly these:

• Unexpected results. The specification asserts (i) "greatest stability seen at the lowest palonosetron concentrations," and (ii) Example 3 — mannitol "showed superior stability" over sodium chloride. Helsinn's opposition record in the European counterpart (declarations of Bonadeo, Calderari, and Waldo Mossi; annexes cited at pages "Annex 1‑3 … EP Serial No. 04 706 657.6") and the 37 C.F.R. § 1.132 declarations filed in US 11/388,270 (Bonadeo, Jun. 8, 2009) are the sort of evidence used to rebut predictability. The counter is that Example 3's mannitol/NaCl comparison is a single‑variable result well within routine optimization, and that the claimed concentration range is too broad to be commensurate with any narrow unexpected effect (the In re Corkill / "scope of the claims" problem).
• Long‑felt need / commercial success. Aloxi's commercial success and the low‑dose bolus advantage (10–60 s IV push) support a nexus argument, but "the claimed invention" must be the source of the success; here the success is plausibly attributable to palonosetron's inherent potency/half‑life (already disclosed in the '333 reference), not to the excipient combination.
• Copying / industry response. The "Families Citing this family" list (CN100336508C "Stable palonosetron injection"; CN100455286C "Palonosetron injection"; WO2010/077669A2 Teva "Palonosetron formulation") shows later competitors arrived at the same excipient set — evidence that the solution was readily discoverable, i.e., that a POSITA would have reached it.
• The on‑sale‑bar overlay. As noted in the prior litigation section, the Federal Circuit's Helsinn v. Teva decision (855 F.3d 1356 (Fed. Cir. 2017), aff'd 139 S. Ct. 628 (2019)) held the ALOXI formulation patents not valid on the on‑sale bar, but the reported invalidity holding mapped to US 7,947,724, 7,947,725, 7,960,424, and 8,598,219 — not to the '981. I reiterate: I have no verified authority that the '981 itself was invalidated. The '981 instead expired by its own term (Jan. 30, 2024).

8. Caveats, contradictions, and open verification items

1. Priority-date sensitivity. If the Claim 1 subject matter is not entitled to the Jan. 30, 2003 priority date (e.g., a written‑description/§ 112 problem as to "terminally sterilizing" or the 0.03–0.2 mg/mL range, given that the family includes a separate continuation‑in‑part, US 13/901,437), the effective date could shift to July 21, 2005 (parent 11/186,311) or April 14, 2011. That shift would make the Aloxi FDA approval letter (Jul. 25, 2003) and the Aloxi PI (2008) — both cited in the NPL — squarely available as § 102(a)/(b) prior art, materially strengthening every combination above (the PI discloses the exact 0.05 mg/mL unit dose). This is the single biggest swing factor in the analysis.
2. Family members are not prior art. US 7,947,724; 7,947,725; 7,960,424; 8,598,218; 8,598,219 and WO2004/067005 appear in the "Citations" list but share the '981's priority chain and must not be used as prior art.
3. Unverified reference texts. I have mapped the references by their titles/assignees/dates as listed on the patent page. I have not independently read US 6,294,548, US 2001/0020029, DE19833119A1, CN1525856A, or WO2004045615A1, and I cannot state with certainty which of them disclose EDTA, mannitol, or terminal sterilization specifically. Those specifics should be confirmed against the primary documents before any rejection is finalized.
4. No PTAB holding on the '981. As noted earlier, I found no IPR/PGR naming US 8,518,981 (the listed challenges target 8,598,219, 8,729,094, and 9,173,942).
5. Not auto-corrected. "Miksztal," "Helsinn Birex Pharmaceutials" (sic in one assignment record), and all patent numbers are reproduced as they appear in the source; '981 is kept distinct from '724/'725/'424/'218/'219/'094 throughout.
6. This is an analytical opinion, not a legal conclusion. A definitive § 103 determination requires the full prosecution file (the Bonadeo § 1.132 declarations and any examiner's reasons for allowance), the complete texts of the secondary references, and evidence of the level of ordinary skill — none of which is fully available from the patent page alone.